This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sherer, Y Articles by Shoenfeld, Y Search for Related Content PubMed PubMed Citation Articles by Sherer, Y Articles by Shoenfeld, Y Social Bookmarking                         What's this?

Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations

Department of Medicine ‘B’ and Center of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel

R Wu

Specialty Laboratory, Santa Monica, California, USA

I Krause

Department of Medicine ‘B’ and Center of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel

J B Peter

Specialty Laboratory, Santa Monica, California, USA

Y Shoenfeld

Department of Medicine ‘B’ and Center of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel; Shoenfeld, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, 52621, Israel Shoenfel{at}post.tau.ac.il

The antiphospholipid syndrome (APS) is characterized by various clinical manifestations and by elevated levels of antiphospholipid antibodies. Passive induction of APS by infusion of these antibodies has been demonstrated in animal models. Intravenous immunoglobulin (IVIg) is one of the therapeutic options in APS. In this study, five commercially used preparations of IVIg were tested for the presence of elevated levels of cardiolipin,ß-glycoprotein-I, phosphatidylserine, antinuclear, and double-stranded DNA autoantibodies, as well as for lupus anticoagulant activity. The absence of abnormal elevated levels of any of these autoantibodies in five different IVIg preparations provides additional evidence for the safety of IVIg use in APS.

Key Words: anti-cardiolipin antibody • antiphospholipid syndrome • ß2-glycoprotein-I • intravenous immunoglobulin

Lupus, Vol. 10, No. 8, 568-570 (2001)
DOI: 10.1191/096120301701549705


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. C. Dalakas and W. M. Clark Strokes, thromboembolic events, and IVIg: Rare incidents blemish an excellent safety record Neurology, June 10, 2003; 60(11): 1736 - 1737. [Full Text] [PDF]